Our vision is to develop superior mAb mixture therapeutics to improve the lives of patients with cancer and other diseases with significant unmet medical needs.
mAb Mixtures and Cancer
- Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress. Data shows clinically meaningful improvement in overall survival in a biomarker-defined patient population with late-stage metastatic colorectal cancer
- Symphogen presents Sym004 Phase 2 data at ESMO 2017 Congress
- Symphogen Names New Chief Financial Officer
- More news